NCT00124098已完成3 期
An Open-Label Study of Aranesp® (Darbepoetin Alfa) Administration Once Every Four Weeks in Anaemic Chronic Kidney Disease (CKD) Subjects
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 主要终点
- Haemoglobin level
研究概览
简要总结
The purpose of this study is to assess if Aranesp® administered once every 4 weeks to chronic kidney disease subjects is safe and efficacious in maintaining haemoglobin levels greater than or equal to 100 g/L.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of chronic kidney disease and not expected to initiate dialysis for the duration of the study
- •Creatinine clearance greater than 15 and less than 40 mL/min as estimated by the Cockroft-Gault equation:
- •Creatinine Clearance = (140-age in years) x body weight in kg/serum creatinine (mg/dL) x
- •For women, the value will be multiplied by 0.85
- •Receiving stable every other week subcutaneous doses of Aranesp®.
- •A stable dose is defined as less than or equal to 25% change in Aranesp® dose over the 6-week period immediately prior to enrollment and with no more than
- •1 missed dose over this period
- •At least two haemoglobin values within the target range of 100 to 130 g/L obtained at least 1 week apart and within 5 weeks of the baseline visit
- •Subjects must have a haemoglobin of 100 to 130 g/L at eligibility/baseline
- •Serum ferritin greater than or equal to 100 mg/L or transferrin saturation greater than or equal to 19.5%
- •Serum vitamin B12 and folate levels must be above the lower limit of the normal range of the local laboratory
- •Before any study specific procedure is performed, the subject must provide informed consent for participation in the study
排除标准
- •Anticipating, scheduled for, or a prior recipient of a kidney transplant
- •Uncontrolled hypertension (blood pressure greater than 160/100 mmHg during the eligibility/baseline period on 2 separate measurements)
- •Congestive heart failure (New York Heart Association [NYHA] class III or IV)
- •Clinical evidence of severe hyperparathyroidism (parathyroid hormone level greater than 1500 pg/mL or biopsy-proven bone marrow fibrosis)
- •Major surgery within 12 weeks before enrollment (excluding vascular access surgery)
- •Active chronic inflammatory process
- •Currently receiving antibiotic therapy for systemic infection
- •ALT or AST greater than 2 times the upper limit of normal range
- •Known positive HIV antibody or positive hepatitis B surface antigen
- •Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
- •Red blood cell transfusions within 8 weeks before eligibility visit or active bleeding
- •Systemic hematologic disease (e.g., sickle cell anaemia, myelodysplastic syndromes, hematologic malignancy, myeloma, haemolytic anaemia)
- •Psychiatric or any other disorder which may impact (in the judgment of the Investigator) the ability to give informed consent for participation in this study
- •Pregnant or breast feeding women
- •All subjects must practice adequate contraception in the judgment of the Investigator, during the course of their participation in the trial
- •Previous entry in this study
- •Treatment with an investigational agent other than Aranesp® or device within 30 days before the first dose of study drug or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study
结局指标
主要结局
Haemoglobin level
次要结局
- Blood pressure
- Aranesp® doses
- Adverse events
- Laboratory parameters
研究者
相似试验
终止
2 期
Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate CancerAnemiaProstatic NeoplasmsNCT00381836University of Aarhus140
已完成
3 期
Darbepoetin Treatment of Anemia in Children With Chronic Renal FailureKidney Failure, ChronicNCT00213291The Hospital for Sick Children40
已完成
不适用
European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin AlfaChronic Kidney DiseaseNCT00838097Amgen321
已完成
4 期
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic HemodialysisEnd Stage Renal DiseaseNCT00117104Amgen
已完成
3 期
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric PracticesSchizophrenia and Schizoaffective DisorderNCT00292409Otsuka Pharmaceutical Development & Commercialization, Inc.400